Common Prothrombotic Gene Mutations in Cerebral Venous Sinus Thrombosis in North-West of Iran

Elyar Sadeghi-Hokmabadi, E. Sakhinia, M. Farhoudi, Somayyeh Hasaneh, M. Ghojazadeh, M. Farzi, S. Andalib, M. Nemati, Omid Abbaszadeh, R. Rikhtegar, Reshad Mirnour
{"title":"Common Prothrombotic Gene Mutations in Cerebral Venous Sinus Thrombosis in North-West of Iran","authors":"Elyar Sadeghi-Hokmabadi, E. Sakhinia, M. Farhoudi, Somayyeh Hasaneh, M. Ghojazadeh, M. Farzi, S. Andalib, M. Nemati, Omid Abbaszadeh, R. Rikhtegar, Reshad Mirnour","doi":"10.4236/NM.2017.84009","DOIUrl":null,"url":null,"abstract":"Objective: Cerebral venous sinus thrombosis (CVST) is a life-threatening cerebrovascular disease which has high prevalence and mortality rate in Iran. Thrombophilia caused by gene mutation is a common cause of CVST. The present study aimed at assessing the prevalence of thrombophilic gene mutations in Iranian CVST patients and then comparing it with normal population. Materials and methods: In a case-control study, polymerase chain reaction-restriction fragment length polymorphism (PCR_RFLP) and amplification-refractory mutation system (ARMS-PCR) were carried out to detect common thrombophilic mutations in 70 CVST patients. Next, it was compared with 82 sex- and age-matched healthy controls. Results: Factor-V-Leiden, Factor-V-Leiden HR2, Factor prothrombin II, MTHFR (667C/T) and MTHFR (1298A/C) prevalence were significantly high in cases of CVST as compared to the controls (P values: 0.012, 0.019, 0.007 and 0.036, respectively). However, there was no significant difference between the two groups in plasminogen activator inhibitor (PAI), angiotensin-converting enzyme (ACE), beta-fibrinogen (FGB), Factor VIII, Factor XIII, and tissue plasminogen activator (tPA) mutations. Conclusion: The findings of the present study suggest that Factor V-Leiden, Factor-V-Leiden HR2, prothrombin II (G20210A), and MTHFR (667C/T & 1298A/C) mutations are more frequent in CVST. Detection of these mutations may help clinicians to decide on the duration of treatment and referral to genetic counseling for valuable prevention.","PeriodicalId":19381,"journal":{"name":"Neuroscience and Medicine","volume":"5 1","pages":"68-76"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience and Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/NM.2017.84009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Objective: Cerebral venous sinus thrombosis (CVST) is a life-threatening cerebrovascular disease which has high prevalence and mortality rate in Iran. Thrombophilia caused by gene mutation is a common cause of CVST. The present study aimed at assessing the prevalence of thrombophilic gene mutations in Iranian CVST patients and then comparing it with normal population. Materials and methods: In a case-control study, polymerase chain reaction-restriction fragment length polymorphism (PCR_RFLP) and amplification-refractory mutation system (ARMS-PCR) were carried out to detect common thrombophilic mutations in 70 CVST patients. Next, it was compared with 82 sex- and age-matched healthy controls. Results: Factor-V-Leiden, Factor-V-Leiden HR2, Factor prothrombin II, MTHFR (667C/T) and MTHFR (1298A/C) prevalence were significantly high in cases of CVST as compared to the controls (P values: 0.012, 0.019, 0.007 and 0.036, respectively). However, there was no significant difference between the two groups in plasminogen activator inhibitor (PAI), angiotensin-converting enzyme (ACE), beta-fibrinogen (FGB), Factor VIII, Factor XIII, and tissue plasminogen activator (tPA) mutations. Conclusion: The findings of the present study suggest that Factor V-Leiden, Factor-V-Leiden HR2, prothrombin II (G20210A), and MTHFR (667C/T & 1298A/C) mutations are more frequent in CVST. Detection of these mutations may help clinicians to decide on the duration of treatment and referral to genetic counseling for valuable prevention.
伊朗西北部脑静脉窦血栓形成常见的血栓前基因突变
目的:脑静脉窦血栓形成(CVST)是一种危及生命的脑血管疾病,在伊朗发病率和死亡率都很高。基因突变引起的血栓形成是CVST的常见病因。本研究旨在评估伊朗CVST患者中亲血栓基因突变的患病率,并将其与正常人群进行比较。材料与方法:采用聚合酶链反应-限制性片段长度多态性(PCR_RFLP)和扩增-难解突变系统(ARMS-PCR)检测70例CVST患者常见的亲血栓性突变。接下来,将其与82名性别和年龄匹配的健康对照进行比较。结果:CVST患者中因子- v - leiden、因子- v - leiden HR2、凝血酶原II、MTHFR (667C/T)和MTHFR (1298A/C)的患病率显著高于对照组(P值分别为0.012、0.019、0.007和0.036)。然而,两组在纤溶酶原激活物抑制剂(PAI)、血管紧张素转换酶(ACE)、β -纤维蛋白原(FGB)、因子VIII、因子XIII和组织纤溶酶原激活物(tPA)突变方面无显著差异。结论:V-Leiden因子、V-Leiden因子HR2、凝血酶原II (G20210A)、MTHFR (667C/T和1298A/C)突变在CVST中更为常见。检测这些突变可以帮助临床医生决定治疗的持续时间和转介到遗传咨询有价值的预防。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信